Company intelligence / Profile preview

BiOkuris

Ownership: Private
Development stage: Commercial

Overview

BiOkuris has developed next-generation medical nutrition products targeting unmet needs in chronic intestinal diseases. Their solutions are designed to improve both the physiopathology and quality of life for patients suffering from conditions like Crohn’s disease and ulcerative colitis. The company is actively conducting clinical studies, including a recent study enrolling its first patient for a medical food product aimed at Crohn's disease[2]. Products are already present on the market.

Therapeutic areas: Gastroenterology
Modalities: Medical nutrition products (based on natural biopolymers such as chitin-glucan and chitosan)
Industry: Non-Drug Biotech

Drug pipeline

1 asset

BK001

Commercial

Indications: Gas-related gastrointestinal disorders

Beyond the preview

Go deeper on BiOkuris.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BiOkuris.

Explore the full profile